Researchers are excited about the medication , a novel dual treatment showing promising outcomes in initial trials for weight loss . It acts by targeting both pathways : GLP-1 and GIP, which , when activated , assist control cravings and improve energy expenditure . Initial reports demonstrate noteworthy weight management and potential advantages f